Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma

British Journal of Haematology

Volumn 147, Issue 1, 2009, Pages 97-101

  Dickinson, Michael ^a   Ritchie, David ^a,b   Deangelo, Daniel J ^c   Spencer, Andrew ^d   Ottmann, Oliver G ^e   Fischer, Thomas ^f   Bhalla, Kapil N ^g   Liu, Angela ^h   Parker, Katie ^h   Scott, Jeffrey W ^h   Bishton, Mark ^d   Miles Prince, H ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d ALFRED HOSPITAL   (Australia)

^e GOETHE UNIVERSITY   (Germany)

^f OTTO VON GUERICKE UNIVERSITY   (Germany)

^g MEDICAL COLLEGE OF GEORGIA   (United States)

^h NOVARTIS PHARMA AG   (Switzerland)

Author keywords

HDAC inhibitor; Hodgkin lymphoma; LBH589; Panobinostat

Indexed keywords

FLUORODEOXYGLUCOSE F 18; PANOBINOSTAT;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE ESCALATION; FATIGUE; FEMALE; HODGKIN DISEASE; HUMAN; HYPERBILIRUBINEMIA; MALE; METABOLISM; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SEPSIS; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADOLESCENT; ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUORODEOXYGLUCOSE F18; HISTONE DEACETYLASE INHIBITORS; HODGKIN DISEASE; HUMANS; HYDROXAMIC ACIDS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 70349194470     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2009.07837.x     Document Type: Article

References (15)

1. Baus, D. Pfitzner, E. (2006) Specific function of STAT3, SOCS1, and SOCS3 in the regulation of proliferation and survival of classical Hodgkin lymphoma cells. International Journal of Cancer, 118, 1404 1413.
2. Bhalla, K., Fiskus, W., Herger, B., Rao, R., Ustin, A., Jillella, A. Atadja, P. (2007) Anti-leukemia activity of histone deacetylase (HDAC) inhibitor LBH589 involves depletion of EZH2 and DNA methyltransferase (DNMT) 1 through disruption of their chaperone association with heat shock protein (hsp) 90. Journal of Clinical Oncology (ASCO Abstracts), A10501.
3. Bolden, J.E., Peart, M.J. Johnstone, R.W. (2006) Anticancer activities of histone deacetylase inhibitors. Nature Reviews Drug Discovery, 5, 769 784.
4. Buglio, D., Georgiakis, G.V., Hanabuchi, S., Arima, K., Khaskhely, N.M., Liu, Y.J. Younes, A. (2008) Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood, 112, 1424 1433.
5. Cheson, B.D., Horning, S.J., Coiffier, B., Shipp, M.A., Fisher, R.I., Connors, J.M., Lister, T.A., Vose, J., Grillo-Lopez, A., Hagenbeek, A., Cabanillas, F., Klippensten, D., Hiddemann, W., Castellino, R., Harris, N.L., Armitage, J.O., Carter, W., Hoppe, R. Canellos, G.P. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. Journal of Clinical Oncology, 17, 1244.
6. Ellis, L., Pan, L., Smyth, M.J., George, D.J., McCormack, C., Williams-Truax, R., Atadja, P., Zhao, C., Dugan, M., Culver, K., Johnstone, R. Prince, H.M. (2008) The histone deacetylase inhibitor LBH589 induces responses with associated alterations in gene expression profiles in cutaneous T cell lymphoma. Clinical Cancer Research, 14, 4500 4510.
7. Maiso, P., Carvajal-Vergara, X., Ocio, E.M., Lopez-Perez, R., Mateo, G., Gutierrez, N., Atadja, P., Pandiella, A. San Miguel, J.F. (2006) The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Research, 66, 5781 5789.
8. Niens, M., Visser, L., Nolte, I., Van Der Steege, G., Diepstra, A., Cordano, P., Jarrett, R., Te Meerman, G., Poppema, S. Van Den Berg, A. (2008) Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22. British Journal of Haematology, 140, 527 536.
9. Nishioka, C., Ikezoe, T., Yang, J., Komatsu, N., Bandobashi, K., Taniguchi, A., Kuwayama, Y., Togitani, K., Koeffler, H.P. Taguchi, H. (2008) Histone deacetylase inhibitors induce growth arrest and apoptosis of HTLV-1-infected T-cells via blockade of signaling by nuclear factor kappaB. Leukemia Research, 32, 287 296.
10. O'Connor, O.A., Heaney, M.L., Schwartz, L., Richardson, S., Willim, R., MacGregor-Cortelli, B., Curly, T., Moskowitz, C., Portlock, C., Horwitz, S., Zelenetz, A.D., Frankel, S., Richon, V., Marks, P. Kelly, W.K. (2006) Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. Journal of Clinical Oncology, 24, 166 173.
11. Ottmann, O.G., Spencer, A., Prince, H.M., Bhalla, K.N., Fischer, T., Liu, A., Parker, K., Jalaluddin, M., Laird, G., Woo, M., Scott, J.W. DeAngelo, D.J. (2008) Phase IA/II Study of Oral Panobinostat (LBH589), a Novel Pan-Deacetylase Inhibitor (DACi) Demonstrating Efficacy in Patients with Advanced Hematologic Malignancies. Blood (ASH Annual Meeting Abstracts), 112, 958.
12. Skinnider, B. (2002) The role of cytokines in classical Hodgkin lymphoma. Blood, 99, 4283 4297. (Pubitemid 34627193)
13. Spencer, A., Prince, H.M., De Angelo, D.J., Fischer, T., Bhalla, K., Giles, F., Liu, A., Parker, S., Laird, G., Masson, E., Rediske, J., Scott, J.W. Oliver, O.G. (2007) Phase IA/II Study of Oral LBH589, a Novel Deacetylase Inhibitor (DACi), Administered on 2 Schedules, in Patients with Advanced Hematologic Malignancies. Blood (ASH Annual Meeting Abstracts), 110, A907.
14. Younes, A., Pro, B., Fanale, M., McLaughlin, P., Neelapu, S., Fayad, L., Wedgwood, A., Buglio, D., Patterson, T., Dubay, M., Li, Z., Martell, R.E., Ward, M.R. Bociek, R.G. (2007) Isotype-Selective HDAC Inhibitor MGCD0103 Decreases Serum TARC Concentrations and Produces Clinical Responses in Heavily Pretreated Patients with Relapsed Classical Hodgkin Lymphoma (HL). Blood (ASH Annual Meeting Abstracts), 110, 2566.
15. Zhou, Q., Agoston, A.T., Atadja, P., Nelson, W.G. Davidson, N.E. (2008) Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells. Molecular Cancer Research, 6, 873 883.